SLC16A7 and cancer: Inhibitors of GLUD1 (to block glutamate metabolism) are highly toxic to the brain60, whereas the lactate flux inhibitor AZD3965 in several anti-cancer clinical trials targets both MCT1 and MCT2 so will also impair brain metabolism61.